- Home
- CWCO vs ERAS Comparison
CWCO vs ERAS Comparison
Compare CWCO & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWCO
- ERAS
- Stock Information
- Founded
- CWCO 1973
- ERAS 2018
- Country
- CWCO Cayman Islands
- ERAS United States
- Employees
- CWCO N/A
- ERAS N/A
- Industry
- CWCO Water Supply
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CWCO Utilities
- ERAS Health Care
- Exchange
- CWCO Nasdaq
- ERAS Nasdaq
- Market Cap
- CWCO 473.0M
- ERAS 484.4M
- IPO Year
- CWCO N/A
- ERAS 2021
- Fundamental
- Price
- CWCO $29.29
- ERAS $1.40
- Analyst Decision
- CWCO
- ERAS Strong Buy
- Analyst Count
- CWCO 0
- ERAS 6
- Target Price
- CWCO N/A
- ERAS $4.83
- AVG Volume (30 Days)
- CWCO 93.5K
- ERAS 779.4K
- Earning Date
- CWCO 08-11-2025
- ERAS 08-19-2025
- Dividend Yield
- CWCO 1.90%
- ERAS N/A
- EPS Growth
- CWCO N/A
- ERAS N/A
- EPS
- CWCO 1.67
- ERAS N/A
- Revenue
- CWCO $127,992,628.00
- ERAS N/A
- Revenue This Year
- CWCO $2.26
- ERAS N/A
- Revenue Next Year
- CWCO $57.33
- ERAS N/A
- P/E Ratio
- CWCO $17.60
- ERAS N/A
- Revenue Growth
- CWCO N/A
- ERAS N/A
- 52 Week Low
- CWCO $22.69
- ERAS $1.01
- 52 Week High
- CWCO $31.30
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- CWCO 49.79
- ERAS 43.81
- Support Level
- CWCO $28.73
- ERAS $1.34
- Resistance Level
- CWCO $29.54
- ERAS $1.54
- Average True Range (ATR)
- CWCO 0.60
- ERAS 0.12
- MACD
- CWCO -0.11
- ERAS -0.02
- Stochastic Oscillator
- CWCO 44.95
- ERAS 12.77
About CWCO Consolidated Water Co. Ltd.
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.